Education And Debate Synthesising licensing data to assess drug safety BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7438.518 (Published 26 February 2004) Cite this as: BMJ 2004;328:518 Article Related content Metrics Responses Peer review Related articles Editorial What doesn't work and how to show it Published: 26 February 2004; BMJ 328 doi:10.1136/bmj.328.7438.473 Editorial Do patients’ preferences matter? Published: 31 October 2008; BMJ 337 doi:10.1136/bmj.a2034 Letter The age hypothesis does not stand up to scrutiny Published: 03 December 2012; BMJ 345 doi:10.1136/bmj.e8149 Letter Concerns about the latest NICE draft guidance on statins Published: 09 July 2014; BMJ 349 doi:10.1136/bmj.g4130 See more Government pulls £100m funding for weight management services after just a year BMJ April 14, 2022, 377 o984; DOI: https://doi.org/10.1136/bmj.o984 Sixty seconds on . . . AI heart checks BMJ March 14, 2022, 376 o667; DOI: https://doi.org/10.1136/bmj.o667 Six in 10 US women have poor cardiovascular health before pregnancy, study finds BMJ February 16, 2022, 376 o402; DOI: https://doi.org/10.1136/bmj.o402 Covid-19: Even mild infections can cause long term heart problems, large study finds BMJ February 14, 2022, 376 o378; DOI: https://doi.org/10.1136/bmj.o378 NICE approves new cholesterol lowering drug after NHS strikes deal with manufacturer BMJ September 01, 2021, 374 n2143; DOI: https://doi.org/10.1136/bmj.n2143 Cited by... Concerns about the latest NICE draft guidance on statinsFulltext PDF The age hypothesis does not stand up to scrutinyFulltext PDF Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trialsFulltext PDF Abstract Do patients' preferences matter?Fulltext PDF Abstract Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004Fulltext PDF Abstract Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectivesFulltext PDF Abstract Transparency in drug regulation: Mirage or oasis?Fulltext PDF Abstract Benefits and harms of drug treatmentsFulltext PDF Abstract The best type of trialFulltext PDF Abstract What doesn't work and how to show itFulltext PDF Abstract
